Education
About Us
Working with TipRanks
Follow Us
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (HK:6821)
:6821
6821 Stock Chart & Stats
HK$73.80
-HK$0.50(-1.06%)
At close: 4:00 PM EST
HK$73.80
-HK$0.50(-1.06%)
Day’s Range― - ―
52-Week RangeHK$39.95 - HK$116.60
Previous CloseN/A
Volume191.84K
Average Volume (3M)640.69K
Market Cap
HK$39.98B
Enterprise ValueHK$27.15B
Total Cash (Recent Filing)HK$7.56B
Total Debt (Recent Filing)HK$318.56M
Price to Earnings (P/E)25.8
Beta1.46
Next Earnings
Mar 31, 2026Next Dividend Ex-DateN/A
Dividend Yield1.57%
Share Statistics
EPS (TTM)0.55
Shares Outstanding27,834,510
10 Day Avg. Volume442,016
30 Day Avg. Volume640,687
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.02
Price to Sales (P/S)2.95
P/FCF Ratio137.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage meaningfully reduces refinancing and downturn risk, giving Asymchem durable financial flexibility. This supports multi-year customer contracts, capacity investments, and R&D funding without reliance on frequent capital markets access, strengthening resilience over cycles.
Healthy Gross And Net MarginsSustained high gross margins and reasonably healthy net margins reflect pricing power and operational efficiency in complex small-molecule CDMO work. Margins provide buffer vs. pricing pressure and support reinvestment into GMP capacity and technical capabilities over the medium term.
Integrated CDMO Service OfferingEnd-to-end capabilities (process R&D to commercial API supply) create multi-stage customer relationships and higher switching costs. This diversified service mix supports recurring commercial supply contracts and milestone revenues, improving long-term revenue visibility and client retention potential.
Bears Say
Weakening Revenue TrendSequential multi-year revenue contraction signals structural softness in demand or portfolio mix shifts. Lower top-line momentum can depress utilization of specialized GMP capacity and limit operating leverage, making it harder to restore prior profit and growth trajectories over the next several quarters.
Weak Cash Conversion And Volatile FCFSubpar cash conversion and variable free cash flow reduce internal funding for capex and working-capital needs. Even with low debt, this volatility forces reliance on retained earnings or equity to fund expansion, increasing execution risk for capacity investments and reducing buffer for shocks.
Compressed Profitability And Lower ReturnsDeclining ROE and material margin compression versus peak years indicate reduced capital efficiency and lower returns on invested capital. Sustained lower profitability can constrain reinvestment, weaken ability to win price-sensitive contracts, and limit long-term shareholder value creation.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H News
6821 FAQ
What was Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price range in the past 12 months?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H lowest stock price was HK$39.95 and its highest was HK$116.60 in the past 12 months.
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap is HK$39.98B.
When is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date is Mar 31, 2026 which is in 35 days.
How were Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s earnings last quarter?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H released its earnings results on Oct 30, 2025. The company reported HK$0.546 earnings per share for the quarter, beating the consensus estimate of HK$0 by HK$0.546.
Is Asymchem Laboratories (Tianjin) Co., Ltd. Class H overvalued?
According to Wall Street analysts Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price is currently Overvalued.
Does Asymchem Laboratories (Tianjin) Co., Ltd. Class H pay dividends?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H pays a Annually dividend of HK$1.202 which represents an annual dividend yield of 1.57%. See more information on Asymchem Laboratories (Tianjin) Co., Ltd. Class H dividends here
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate is 0.
How many shares outstanding does Asymchem Laboratories (Tianjin) Co., Ltd. Class H have?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H has 27,834,510 shares outstanding.
What happened to Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price movement after its last earnings report?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H reported an EPS of HK$0.546 in its last earnings report, beating expectations of HK$0. Following the earnings report the stock price went down -2.166%.
Which hedge fund is a major shareholder of Asymchem Laboratories (Tianjin) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6821
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.63%
12-Months-Change
Fundamentals
Return on Equity
6.00%
Trailing 12-Months
Asset Growth
8.02%
Trailing 12-Months
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) Earnings & Revenues
Technical Analysis
Genscript Biotech
―
Pharmaron Beijing Co., Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---